Rothband (WSR Medical Solutions Ltd)’s Post

US HCPs: #MIDWAY 62 supporting FREDx deployment, telescoped Pipeline deployment, and balloon angioplasty for management of hypophyseal ICA aneurysm. Supported by #BMX81. Thank you for sharing Dr. Diaz! Rx only. Risk: peninc.info/risk Clinical results may vary

55y/f, having recurrent headache and TIA. MRA detected left ICA aneurysm. Flow diverter done for the same. Pipeline vantage deployed with good stasis within the aneurysm post deployment. 2nd flow diverter of this week. Patient got discharged in neurologically intact condition. Thanks Divyansh Sengar and medtronics NV team for all the support. #Flowdiverter #Pipelinevantage #Minimallyinvasiveneurosurgery

Simplify the Complex 💪 The SiLO TFX™ Procedure offers a swift solution to SI Joint dysfunctions. This glimpse into the SiLO TFX procedure highlights the effectiveness of minimally invasive interventions in enhancing patients' quality of life 🚀 #Transfixingthesijoint #sijointsolution #SiLO 🎯 #gamechanging

Do you want to know the latest about the world’s first transcatheter tricuspid valve replacement (TTVR) system*? This broadcast is for you! Register now and learn from a panel of experts about the potential of our TTVR system to eliminate tricuspid regurgitation.** Register here: https://ow.ly/749V30sBx4s #tricuspidvalve #TTVR #interventionalcardiology #Edwardslifesciences #EdwardsEmployees *First-of-its-kind device commercially available (in the EU). **In a paired analysis of the first 150 patients in the TRISCEND II trial, 77.8% of EVOQUE+OMT patients achieved TR reduction to none/trace at 6 months follow-up (n=81)

Do you want to know the latest about the world’s first transcatheter tricuspid valve replacement (TTVR) system*? This broadcast is for you! Register now and learn from a panel of experts about the potential of our TTVR system to eliminate tricuspid regurgitation.** Register here: https://ow.ly/AGJ030sBB2s #tricuspidvalve #TTVR #interventionalcardiology #Edwardslifesciences #EdwardsEmployees *First-of-its-kind device commercially available (in the EU). **In a paired analysis of the first 150 patients in the TRISCEND II trial, 77.8% of EVOQUE+OMT patients achieved TR reduction to none/trace at 6 months follow-up (n=81)

Do you want to know the latest about the world’s first transcatheter tricuspid valve replacement (TTVR) system*? This broadcast is for you! Register now and learn from a panel of experts about the potential of our TTVR system to eliminate tricuspid regurgitation.** Register here: https://ow.ly/Ikc130sBx5G #tricuspidvalve #TTVR #interventionalcardiology #Edwardslifesciences #EdwardsEmployees *First-of-its-kind device commercially available (in the EU). **In a paired analysis of the first 150 patients in the TRISCEND II trial, 77.8% of EVOQUE+OMT patients achieved TR reduction to none/trace at 6 months follow-up (n=81)

Do you want to know the latest about the world’s first transcatheter tricuspid valve replacement (TTVR) system*? This broadcast is for you! Register now and learn from a panel of experts about the potential of our TTVR system to eliminate tricuspid regurgitation.** Register here: https://ow.ly/1fjU30sBxf2 #tricuspidvalve #TTVR #interventionalcardiology #Edwardslifesciences #EdwardsEmployees *First-of-its-kind device commercially available (in the EU). **In a paired analysis of the first 150 patients in the TRISCEND II trial, 77.8% of EVOQUE+OMT patients achieved TR reduction to none/trace at 6 months follow-up (n=81)

We’re thrilled to share that our subsidiary, Kardiolytics Inc, has been granted a new patent in the United States, marking a significant milestone in our journey towards revolutionizing cardiac care. The patent, numbered US20240120110A1, recognizes our method of numerical modeling of blood flow in arteries—a vital component of our #VCAST technology. What does this mean for healthcare? 🏥 Our patented method allows for precise analysis of arterial blood flow, enabling clinicians to assess atherosclerotic plaque surface deformation and stress—an invaluable tool in diagnosing coronary artery disease. Przemek Tadla, CTO at Medicalgorithmics and COO at Kardiolytics, shares his thoughts: “This new patent underscores the medical and commercial potential of the VCAST technology. It highlights our innovation and strengthens the competitive edge and protection of our technology.” But that’s not all! 🚀 We’re also making strides in regulatory approval processes. With CE certification initiation in the EU and plans for FDA approval in the US, we’re on track to bring VCAST to patients worldwide, offering a non-invasive, hospitalization-free diagnostic solution for coronary artery disease. Stay tuned as we continue to push the boundaries of innovation in cardiac care with VCAST technology: https://lnkd.in/eSMWKcts #Medicalgorithmics #VCAST #Innovation #CardiacCare #HealthTech

A perfect opportunity to convince yourself of the benefits of an efficient reporting workflow in LCS scenarios.

Exciting news today as Biosense Webster receives European CE mark approval for our VARIPULSE™ Platform, marking a significant step forward in treating cardiac arrhythmia with pulsed field ablation (PFA) technology. With estimates suggesting that by 2050, Europe will have the greatest increase in Atrial Fibrillation compared to other regions globally, this milestone not only signifies our commitment to innovation in cardiac care but also positions us here in Europe at the forefront of solving some of the most pressing challenges in cardiac care. Our focus now is working alongside physicians and healthcare providers, together with our leading clinical teams throughout the region to bring this technology to all those patients who can benefit. https://lnkd.in/edYARrJz #myCompany #CardiacCare #JNJMedTechProud #VARIPULSE #PulsedFieldAblation